.25 mg semaglutide Wegovy Injection 0.25 (Semaglutide) Ozempic (Semaglutide Injection) 0.25mg or

It remains a research-only compound available for laboratory and investigational use

Skyes CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model Skye shares new preclinical DIO data at virtual KOL event Nimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment weight loss compared to tirzepatide Nimacimab reduced rebound weight gain following treatment with tirzepatide or nimacimab + tirzepatide Nimacimab outperformed monlunabant head-to-head, and is uniquely positioned as a well-tolerated therapeutic to potentially induce healthier and sustained weight loss, both as a monotherapy, combination and maintenance therapy Top-line data from Phase 2 CBeyond TM study expected to be reported in late Q3/early Q4 2025 SAN DIEGO, Sept

Eating more slowly, staying hydrated, managing your stress, and getting enough sleep can all support successful weight loss

They are not magic